CD123-ENG T-cells

CD123-ENG T-cells are genetically engineered human T cells that are modified to secrete bispecific T-cell engager molecules targeting CD123 (interleukin-3 receptor alpha subunit, highly expressed in acute myeloid leukemia cells) and CD3 (an essential part of the T-cell receptor complex). These cells recognize and kill CD123-positive leukemia cells in an antigen-dependent manner, and can also redirect bystander (untransduced) T cells to kill CD123-positive tumor cells through secretion of the bispecific engager[1][2][3][4][5]. The approach differs from chimeric antigen receptor (CAR) T cells by engaging native T-cell signaling and recruiting broader T-cell immune responses. Preclinical studies show anti-leukemic efficacy both in vitro and in AML xenograft mouse models. Variations such as addition of suicide genes (e.g., CD20) or supportive cytokines (e.g., IL-15) have been developed to improve efficacy, persistence, and safety[1][2][3][5]. The primary indication is immunotherapy for acute myeloid leukemia (AML).

Other names

CD123-ENGCD-123-ENGCD 123-ENGCD123.ENG T cellsCD-123.ENG T cellsCD 123.ENG T cellsCD123-specific ENG T cellsCD-123-specific ENG T cellsCD 123-specific ENG T cells